Advocacy

Advocacy in Action

June 10, 2021

Telehealth and Payment for Audio-Only Visits

Expansion of telehealth coverage is important to many Endocrine Society members.  During the pandemic, the Endocrine Society has successfully advocated to obtain Medicare waivers to expand coverage and to provide payment parity for audio-only visits.  Most recently we worked with Senators Joe Manchin (D-WV), Kevin Cramer (R-ND) and Jeanne Shaheen (D-NH) to urge the Senate Appropriations Committee to include language in its fiscal year 2022 appropriations bill encouraging the Department of Health and Human Services to review the data collected on audio-only services in order to obtain greater access to healthcare for patients in rural and underserved communities.  As a result of our advocacy, specifically our recent online advocacy campaign, 1bipartisan Senators joined  the Manchin-Cramer-Shaheen effort.  In addition, Senator Manchin has also introduced legislation to ensure that healthcare providers are able to continue offering audio-only telehealth appointments after the public health emergency ends. During these times when in-person meetings with legislators are not possible, online campaigns are even more crucial to making sure your voice is heard.  Your advocacy helped make a difference!

Eric Lander Sworn in as New Director of Office of Science and Technology Policy

The US Senate confirmed Eric Lander, PhD as the Director of the Office of Science and Technology Policy (OSTP) and Dr. Lander was sworn into this position. In a move to give greater attention to science, President Joe Biden had previously announced that the OSTP Director would now have a seat in his cabinet. In a letter addressed to the research communityDr. Lander described the weight of the responsibility of the new role and the need for collaboration with all people who believe science and technology can make a better, safer, and more just world. The Endocrine Society had supported the inclusion of the OSTP Director as a member of the cabinet. We have also offered our congratulations to Dr. Lander and requested a meeting to discuss issues of mutual interest such as funding of biomedical research;diversity, equity, and inclusion in the research workforce; scientific publishing; endocrine-disrupting chemicals; and climate change and health.

National Science Foundation Legislation

The Senate passed S 1260, the US Innovation and Competition Act (USICA) this week.  The approximately 2000-page bill would authorize significant funding for the National Science Foundation to support research (note: actual funding still would need to be provided through the annual appropriations process). In addition to several good provisions related to diversity, equity, and inclusion in the research workforce and related to removing administrative burdens in research, the Senate bill also contains troublesome language that could change the federal policy on public access publication by reducing the embargo period and shifting the cost of publications onto researchers as well as language that could remove certain protections for the reuse of material.  The House of Representatives is expected to develop its own version of the bill over the summer.  The Endocrine Society is monitoring developments and is working with other research organizations to support helpful provisions and with other professional societies who publish journals on to modify the public access language.

Drug Pricing House, Senate, and Administration Moves

President Joe Biden’s proposed budget partially embraces the thorny issue of drug pricing by voicing support for legislation to give Medicare more power to negotiate on drug prices and impose penalties on manufacturers when they raise prices faster than inflation, similar tothe House Democrats' drug pricing bill HR 3President Biden’s budget request does not give details although at a Senate Budget Committee Hearing this week the Deputy Director of the Office of Management and Budget Shalanda Young stated that the budget “makes clear” that the president expects drug pricing legislation this year.

This week House Democrats indicated that they want to include HR 3in a sweeping infrastructure and jobs package currently set for consideration over the summer. The inclusion of HR 3 would almost certainly mean Democrats have given up on striking a bipartisan infrastructure deal and decided to bypass Republicans entirely by using the budget reconciliation process.  Meanwhile amid concerns that HR 3 will not be able to muster 50 votes in the Senate, Senate Finance Committee Chair Ron Wyden (D-OR) is looking at developing an alternative proposal to lower prescription costs and would cut some of the more controversial provisions, including the use of international reference pricing to cap domestic drug prices and the application of federally negotiated Medicare or Medicaid prices to private sector insurance plans.

The Endocrine Society continues to lead efforts calling for action on insulin and other high-cost prescription drugs. We have testified before Congress, shared our position statement, and are developing educational events for congressional staff, including a July Hill Day for clinicians.

Latest Policy Communications

Last Updated:
Take Action

Make Your Voice Heard

Take Action
We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Journals

The Best of Endocrine Society Journals 2020

Explore a collection of top articles published in the Endocrine Society journals in 2020, selected on the basis of citations, downloads, and Altmetric score.

Explore a collection of top articles published in the Endocrine Society journals in 2020, selected on the basis of citations, downloads, and Altmetric score.

Back to top
Short on time?

We'll come to you...

Get updates on the latest breakthroughs, clinical practice guidelines, and career development opportunities, straight to your inbox

Then take the next step: Set up your free website account and get exclusive access to even more great tools & content!